| I. COMMENCED TRADING IN DECEMBER | ||||||||||||||
| Company | Date | Date | Shares/ | Price | Gross | Net | Shares | Fully | Lead | |||||
| (Symbol) | Filed | Comm. | Units | Per Share/ | (M) | (M) | Out | Dil. | Underwriters | |||||
| (M) | Unit | (M) | (M) | |||||||||||
| INITIAL OFFERINGS | ||||||||||||||
| Antisoma plc* | 11/24 | 12/17 | 28.6S | $0.588 | $16.8 | $15.5 | 71.4 | ND | NI; AS; PU | |||||
| (EASDAQ:ASOM) | ||||||||||||||
| TOTAL: $16.8M | ||||||||||||||
| NOTE: | ||||||||||||||
| * Antisoma plc completed its initial public offering on Easdaq. The company issued 28.6M new common shares at 35p each (US$0.588) for a total of £10M (US$16.8M). Existing investors agreed to purchase one-third of the new shares. (Prices converted at a rate of £0.67/US$1.) | ||||||||||||||
| FOLLOW-ON OFFERINGS | ||||||||||||||
| Anesta Corp. | 11/20 | 12/17 | 2.8S | $21.25 | $59.5 | $55.6 | 12.4 | 14.1 | BRS, VBW | |||||
| (NSTA)* | ||||||||||||||
| TOTAL: $59.5M | ||||||||||||||
| NOTE: | ||||||||||||||
| * Anesta Corp. originally registered 2M shares in its follow-on offering; 1.8M to be sold by the company and 0.2M to be sold by selling stockholders. It actually sold 3M shares in the offering, 2.8M by the company and 0.2M by selling stockholders. | ||||||||||||||
| II. FILED AND PENDING | ||||||||||||||
| Company | Date | Shares/ | Price | Shares | Lead, | Value@ | ||||||||
| (Symbol) | Filed | Units (M) | Range | Out (M) | Other UWs | ($M) | ||||||||
| INITIAL OFFERINGS | ||||||||||||||
| Anthra | 3/11; | 2.0U | $5 | 6.9 | JM | $10 | ||||||||
| Pharmaceuticals Inc.* | 11/16 | |||||||||||||
| Invitrogen Corp. | 12/10 | 3.0S | $15 | 12.6 | DLJ; NBMS; WDR | $45 | ||||||||
| Praecis | 8/12 | 3.5S | $14-$16 | 19.2 | BTAB; NBMS | $49 | ||||||||
| Pharmaceuticals Inc. | ||||||||||||||
| NOTES: | ||||||||||||||
| * Anthra Pharmaceuticals Inc. has amended its initial public offering prospectus several times, most recently on 11/16/98. Each unit consists of 1 share of stock and 1 5-year warrant to buy 1 share of stock at $6.00. The company is now planning to list its units, common stock and warrants on the Nasdaq SmallCap Market; previously, it had planned to list the securities on the American Stock Exchange. | ||||||||||||||
| FOLLOW-ON OFFERINGS | ||||||||||||||
| There are no follow-on offerings in registration. | ||||||||||||||
| III. WITHDRAWN OR POSTPONED | ||||||||||||||
| Company | Date | Shares/ | Price | Shares | Lead, | Value@ | ||||||||
| (Symbol) | Filed | Units (M) | Range | Out (M) | Other UWs | ($M) | ||||||||
| Sensus Drug | 7/28 | 3.0S | $13-$15 | 9.6 | ML; NBMS; BRS | $39 | ||||||||
| Development Corp.* | ||||||||||||||
| NOTE: | ||||||||||||||
| * Sensus Drug Development Corp. postponed its initial public offering indefinitely on 12/30/98. The company did not state a reason. | ||||||||||||||
| OTHER NOTES: | ||||||||||||||
| E = estimated; ND = not disclosed, reported and/or available; S = shares; U = units; W = warrants | ||||||||||||||
| "Date filed" indicates the date on which the company announced that it had filed a preliminary prospectus with the Securities and Exchange Commission for its offering. It is not necessarily the same date as that which is printed on the preliminary prospectus itself. | ||||||||||||||
| In completed offerings, the number of shares sold includes the overallotment (in full or in part) if that option has been exercised by the time this publication goes to press. | ||||||||||||||
| Shares outstanding refers to the number of shares outstanding after the public offering. In the case of those offerings which are still pending, it assumes that the number of shares sold in the offering will be equal to the number intended for sale as per the prospectus. | ||||||||||||||
| @ Values are estimated from the low-end range for IPOs. | ||||||||||||||
Underwriters' Key:
AS (Aros Securities); BRS (BancBoston Robertson Stephens); BTAB (BT Alex. Brown Inc.); DLJ (Donaldson, Lufkin & Jenrette); JM (Janssen/Meyers Associates LP); ML (Merrill Lynch & Co.); NBMS (NationsBanc Montgomery Securities Inc.); NI (Nomura International plc); PU (Puilaetco); VBW (Volpe Brown Whelan & Co.); WDR (Warburg Dillon Read LLC)